TrialsgrambetaRCTs are beautiful

SEQUOIA-HCM

2024

Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM

In 282 patients with symptomatic obstructive HCM, aficamten improved peak oxygen uptake on exercise testing compared with placebo.

Result

Primary endpoint: Change in peak oxygen uptake (pVO2) at 24 weeks

Aficamten increased pVO2 by a least-squares mean difference of 1.74 mL/kg/min (95% CI 1.04-2.44; P<0.001) vs placebo, with improvements in all 10 secondary endpoints.

Original publication
Subtopic
myosin inhibitor
Design
Double-blind placebo-controlled RCT, phase 3
Relevance
Supporting: context rather than must-know.
Source
Maron MS, et al. N Engl J Med. 2024;390(20):1849-1861.doi 10.1056/NEJMoa2401424

Discussion & critique

Functional surrogate endpoint over 24 weeks rather than hard outcomes. Positioned aficamten as a next-generation cardiac myosin inhibitor with a potentially simpler titration/monitoring profile than mavacamten.

Discussed in podcasts